Inclusion Criteria:  Participants with the Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 Participants with a histologically confirmed diagnosis of RCC with any histological origin Participants with a locally advanced/metastatic disease (that is [ie], newly diagnosed Stage 4 RCC per American Joint Committee on Cancer) or has recurrent disease Participants has received 1 or 2 cycles of Avelumab plus Axitinib treatment as a first-line therapy according to the approved Summary of Product Characteristics (SmPC) Participants willing to sign the written informed consent form (ICF) to participate in this study  Exclusion Criteria:  Participants with contraindications for Avelumab or Axitinib according to the approved SmPC Participants who have participated in any interventional clinical study of a drug or device within 28 days prior to the start of Avelumab plus Axitinib